Cargando…
The Editors Respond: The Diminishing Role of Montelukast in Asthma Therapy
We greatly appreciate the additional opportunity to examine the therapeutic value of montelukast in particular and the leukotriene modifiers in general. The true value for money spent on montelukast is a subject of interest to virtually every managed care clinician and administrative pharmacist, as...
Autores principales: | Crownover, Brian K., Curtiss, Frederic R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437451/ http://dx.doi.org/10.18553/jmcp.2006.12.6.487 |
Ejemplares similares
-
The Editors Respond
por: Curtiss, Frederic R.
Publicado: (2010) -
Forecasting Cholesterol Management-End of the Statin Gold Rush?
por: Crownover, Brian K., et al.
Publicado: (2006) -
More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006) -
PP-ICONS-Another Tool to Help Interpret Asthma Utilization Studies
por: Crownover, Brian K.
Publicado: (2006) -
Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)